Patents by Inventor John Anthony Zuris
John Anthony Zuris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12325854Abstract: CRISPR/Cpf1-related compositions and methods for treatment of cancer.Type: GrantFiled: September 4, 2018Date of Patent: June 10, 2025Assignee: EDITAS MEDICINE, INC.Inventors: Gordon Grant Welstead, Hariharan Jayaram, Tongyao Wang, John Anthony Zuris, Christopher Borges
-
Publication number: 20250025572Abstract: The present disclosure relates to Cast 2a effector proteins with increased activity compared to previously described Cas12a effector proteins. The present disclosure also relates to fusion proteins comprising a Cas12a effector protein fused to a deaminase with increased activity compared to previously described fusion proteins comprising a Cast 12a effector protein fused to a deaminase. Systems and methods of their use are also disclosed.Type: ApplicationFiled: November 28, 2022Publication date: January 23, 2025Inventor: John Anthony Zuris
-
Publication number: 20240293543Abstract: Edited cells, e.g., genomically edited cells, with reduced levels of immune rejection and/or improved persistence are described.Type: ApplicationFiled: June 23, 2022Publication date: September 5, 2024Inventor: John Anthony Zuris
-
Patent number: 12049651Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.Type: GrantFiled: December 20, 2021Date of Patent: July 30, 2024Assignee: Editas Medicine, Inc.Inventors: Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
-
Patent number: 12031132Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.Type: GrantFiled: September 11, 2020Date of Patent: July 9, 2024Assignee: EDITAS MEDICINE, INC.Inventors: Jennifer Leah Gori, Edouard Aupepin De Lamothe-Dreuzy, Jack Heath, John Anthony Zuris, KaiHsin Chang
-
Publication number: 20240117383Abstract: Strategies, systems, compositions, and methods for efficient production of knock-in cellular clones without reporter genes. An essential gene is targeted using a knock-in cassette that comprises an exogenous coding sequence for a gene product of interest (or “cargo sequence”) in frame with and downstream (3?) of an exogenous coding sequence or partial coding sequence of the essential gene. Undesired targeting events create a non-functional version of the essential gene, in essence a knock-out, which is “rescued” by correct integration of the knock-in cassette, which restores the essential gene coding region so that a functional gene product is produced and positions the cargo sequence in frame with and downstream of the essential gene coding sequence.Type: ApplicationFiled: December 12, 2023Publication date: April 11, 2024Inventors: John Anthony Zuris, Carrie Marie Margulies
-
Publication number: 20230227856Abstract: Strategies, systems, compositions, and methods for efficient production of knock-in cellular clones without reporter genes. An essential gene is targeted using a knock-in cassette that comprises an exogenous coding sequence for a gene product of interest (or “cargo sequence”) in frame with and downstream (3?) of an exogenous coding sequence or partial coding sequence of the essential gene. Undesired targeting events create a non-functional version of the essential gene, in essence a knock-out, which is “rescued” by correct integration of the knock-in cassette, which restores the essential gene coding region so that a functional gene product is produced and positions the cargo sequence in frame with and downstream of the essential gene coding sequence.Type: ApplicationFiled: May 4, 2021Publication date: July 20, 2023Inventors: John Anthony Zuris, Carrie Marie Margulies, Chew-Li Soh, Peter Tonge, Mark James Tomishima, Conor Brian McAuliffe, Claudio Monetti
-
Publication number: 20220186199Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.Type: ApplicationFiled: December 20, 2021Publication date: June 16, 2022Inventors: Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
-
Patent number: 11236313Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.Type: GrantFiled: April 12, 2017Date of Patent: February 1, 2022Assignee: Editas Medicine, Inc.Inventors: Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
-
Publication number: 20210315994Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.Type: ApplicationFiled: December 22, 2020Publication date: October 14, 2021Applicant: President and Fellows of Harvard CollegeInventors: David R. Liu, David B. Thompson, John Anthony Zuris
-
Patent number: 10912833Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.Type: GrantFiled: April 20, 2018Date of Patent: February 9, 2021Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, David B. Thompson, John Anthony Zuris
-
Publication number: 20200323984Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of functional effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.Type: ApplicationFiled: April 28, 2020Publication date: October 15, 2020Applicant: President and Fellows of Harvard CollegeInventors: Daivd R. Liu, John Anthony Zuris, David B. Thompson
-
Patent number: 10682410Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of functional effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.Type: GrantFiled: September 5, 2014Date of Patent: June 16, 2020Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, John Anthony Zuris, David B. Thompson
-
Publication number: 20190136210Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.Type: ApplicationFiled: April 12, 2017Publication date: May 9, 2019Inventors: Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
-
Patent number: 10258697Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.Type: GrantFiled: October 29, 2015Date of Patent: April 16, 2019Assignee: Massachusetts Eye and Ear InfirmaryInventors: Zheng-Yi Chen, David Liu, John Anthony Zuris, David B. Thompson
-
Publication number: 20190062735Abstract: CRISPR/Cpf1-related compositions and methods for treatment of cancer.Type: ApplicationFiled: September 4, 2018Publication date: February 28, 2019Applicant: EDITAS MEDICINE, INC.Inventors: Gordon Grant Welstead, Hariharan Jayaram, Tongyao Wang, John Anthony Zuris, Christopher Borges
-
Publication number: 20180236081Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.Type: ApplicationFiled: April 20, 2018Publication date: August 23, 2018Applicant: President and Fellows of Harvard CollegeInventors: David R. Liu, David B. Thompson, John Anthony Zuris
-
Patent number: 9999671Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.Type: GrantFiled: October 30, 2014Date of Patent: June 19, 2018Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, David B. Thompson, John Anthony Zuris
-
Patent number: 9737604Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of functional effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.Type: GrantFiled: August 18, 2014Date of Patent: August 22, 2017Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, John Anthony Zuris, David B. Thompson
-
Patent number: 9526784Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of funcational effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.Type: GrantFiled: August 18, 2014Date of Patent: December 27, 2016Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, John Anthony Zuris, David B. Thompson